TRIB

Business Context and Reporting Period

Company: Trinity Biotech plc
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2006
Business Overview: Trinity Biotech develops, manufactures, and markets medical diagnostic test kits and instrumentation for clinical laboratories and point-of-care segments. The company operates globally with manufacturing facilities in Ireland, the US, Sweden, and Germany. The 2006 fiscal year was defined by significant acquisition activity, most notably the purchase of the haemostasis product line from bioMerieux Inc. for US$44.4 million, which expanded the company's portfolio and market share in blood disorder diagnostics.

Key Financial Metrics (IFRS)

Note: Borrowings include interest-bearing loans and convertible notes. Cash excludes restricted cash.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by US$20.1 million (20.4%), driven primarily by the bioMerieux acquisition (contributing US$20.9 million in haemostasis revenue) and the full-year impact of the 2005 Primus Corporation acquisition.
• Inventory Provision: A significant non-cash charge of US$5.8 million was recorded in Cost of Sales. This provision resulted from the decision to discontinue various existing products following the integration of the bioMerieux haemostasis line.
• Profitability Impact: Operating profit declined by 71% to US$1.9 million. Excluding the US$5.8 million inventory provision, operating profit would have increased by 17%. Net profit decreased by 38% to US$3.3 million, mitigated by a net income tax credit of US$2.8 million (compared to a tax expense of US$0.7 million in 2005).
• Debt Expansion: To fund acquisitions, the company increased its bank loan facility by US$30 million to US$43.3 million. Total borrowings rose from US$27.1 million in 2005 to US$45.3 million in 2006. Net financing costs increased by 123% to US$1.5 million.
• US GAAP Reconciliation: Under US GAAP, the company reported a net loss of US$1.9 million for 2006, compared to a profit of US$3.3 million under IFRS. The primary reconciling items were the expensing of capitalized development costs (US$5.9 million) and the treatment of share-based compensation.

Guidance, Outlook, and Risks

Management Commentary & Outlook: Management expects cash flows from operations to be sufficient to support existing operations and repay debt obligations for the next 12 months. The company anticipates significant capital expenditure in 2007 to integrate the bioMerieux manufacturing operations in Ireland. The company does not anticipate paying dividends in the foreseeable future, intending to retain earnings to fund business operations and growth.

Key Risks and Contingencies:

• Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting related to revenue recognition cutoff procedures for goods held at a third-party logistics facility in China. Controls have been enhanced, but the weakness resulted in a conclusion that disclosure controls were not effective as of December 31, 2006.
• Regulatory Compliance: The business is heavily regulated by the FDA and other global authorities. Delays in approvals or non-compliance could materially impact revenues.
• Acquisition Integration: Success depends on the ability to assimilate acquired businesses (bioMerieux, Nephrotek) and realize projected synergies.
• Currency Risk: The company has a "euro deficit" (expenses in euros exceed revenues in euros). A 10% decrease in the value of the euro would have an approximate 3% adverse impact on consolidated revenues.
• Legal Proceedings: A long-standing dispute with Inverness Medical Innovations Inc. regarding a distribution agreement was settled in August 2006, resulting in a royalty-bearing license and a US$1 million reimbursement to Trinity Biotech.

Investor Verification Checklist

• Inventory Provision Validity: Verify the rationale and magnitude of the US$5.8 million inventory write-off related to the bioMerieux integration and assess if similar provisions are likely in future periods.
• Internal Control Remediation: Review the specific steps taken to remediate the material weakness in revenue recognition controls and confirm the effectiveness of these new controls in subsequent filings.
• Debt Covenants: Note that the company was in breach of certain bank covenants at year-end, which were waived. Verify the terms of the amended covenants and the company's ability to maintain compliance.
• US GAAP vs. IFRS: Investors should reconcile the IFRS profit of US$3.3 million with the US GAAP loss of US$1.9 million, specifically focusing on the treatment of capitalized R&D and share-based payments.
• Acquisition Synergies: Monitor the integration progress of the bioMerieux haemostasis line to ensure projected revenue growth and cost synergies are realized.